(WTP) threshold of $150,000/quality-adjusted life-yr (QALY).Results:Assuming a 5-yr PFS of 69.6% with pola-R-CHP and 62.6% with RCHOP, pola-R-CHP was more effective (0.81 incremental QALYs) but more costly ($66,218) and was cost-effective at a WTP of 150,000 (ICER $82,220...
Summary We evaluated the cost‐effectiveness of frontline polatuzumab vedotin‐R‐CHP (pola‐R‐CHP) treatment for patients with diffuse large B‐cell lymphoma (DLBCL) in Germany by using a Markov model (lifetime horizon). Progression rates and survival outcomes were extrapolated from the POLARIX...
PCN238 IS POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE-RITUXIMAB COST-EFFECTIVE FOR PATIENTS IN THE UNITED STATES WITH TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA?doi:10.1016/j.jval.2019.09.433K.A. BettsP.O. ThuressonE.X. Du...
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspectivedoi:10.1007/s40273-024-01421-8Keith CooperEmma Maund...
Subsequent treatments included chemotherapy (R-ESHAP, R-GDP, polatuzumab vedotin plus bendamustine and rituximab, and a combination of methylprednisolone and cyclophosphamide), CAR T-cell therapy, palliative treatment, and even clinical trials. 2.4. Clinical Data Transitions into each of the three heal...
Notably, the POLARIX (NCT03274492), which is a recently published Phase III trial, compared the modified regimen of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) to RCHOP in patients with DLBCL [53]. This regimen substituted vincristine for polatuzumab...